A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Alpelisib (Primary) ; Cisplatin
- Indications Solid tumours
- Focus Adverse reactions
- 18 Jan 2018 Planned end date changed from 1 Mar 2018 to 1 Mar 2020.
- 18 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 02 May 2017 Status changed from not yet recruiting to recruiting.